Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is hypothesized that a strategy using prophylactic oral Tranexamic Acid (TXA) with therapeutic platelet transfusions is safe and effective compared to prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (who are at risk for bleeding).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage

NCT04149171

Hemorrhagic Shock

COMPLETED PHASE3

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

NCT02908516

Hip Fractures Blood Loss

TERMINATED PHASE4

Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures

NCT05518279

Hip Fractures Blood Loss

WITHDRAWN PHASE3

Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures

NCT02580227

Hip Fractures Surgical Blood Loss

UNKNOWN PHASE4

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.

NCT03780894

Polytrauma Traumatic Hemorrhage

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Canada, over 1,500 autologous hematopoietic stem cell transplantations (ASCT) are performed annually for hematologic malignancies. It is currently standard practice to provide a prophylactic transfusion of platelets to prevent bleeding when the daily measured platelet count is less than 10 x 109/L. A patient may require up to six adult platelet doses during the post-transplant period. However, the true benefit of prophylactic platelet transfusions in the ASCT setting is unclear and has been called into question by several recent studies.

Prophylactic platelet transfusions may not only be unnecessary, they may be detrimental to the patient. Among blood products, platelet transfusions are associated with the highest risk of both infectious and non-infectious complications: this would include bacterial infections and allergic /febrile reactions. Moreover, the potential overuse of platelet products places a significant burden on a scarce health care resource that is provided through volunteer donations.

An alternative strategy to prevent bleeding and reduce the need for platelet transfusions involves administering Tranexamic Acid, an oral antifibrinolytic agent to stabilize blood clots and reduce bleeding. Tranexamic Acid is safe and effective in many clinical scenarios, and may be a reasonable alternative for prophylactic platelet transfusions. In the setting of ASCT, Tranexamic Acid may reduce bleeding and further enhance a strategy of therapeutic platelet transfusions where platelets are administered only in the event of active bleeding symptoms.

The effect of prophylactic platelet transfusions and Tranexamic Acid on clinical, quality of life and economic outcomes in patients receiving ASCT is unknown. The primary aim of this research program is to perform a randomized controlled trial to determine whether a strategy of prophylactic Tranexamic Acid (with therapeutic platelet transfusions) is safe and effective compared to prophylactic platelet transfusions in patients undergoing ASCT. Before conducting a larger trial, the investigators first propose a pilot randomized controlled trial to determine the feasibility of such a study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prophylactic Platelet Transfusions

Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10\^9/L.

Group Type NO_INTERVENTION

No interventions assigned to this group

Prophylactic Tranexamic Acid

Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10\^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions

Group Type EXPERIMENTAL

Tranexamic Acid

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic Acid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Patients are aged 18 years old or older and undergoing an autologous HSCT (hematopoietic stem cell transplantation) for any hematologic malignancy.

Exclusion Criteria

1. A previous WHO grade 3 or 4 bleeding event
2. A WHO grade 2 bleeding event within the past year
3. A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis
4. Current or previous (within 2 weeks) urinary tract bleeding
5. An inherited hemostatic or thrombotic disorder
6. Coagulopathy defined as a prothrombin time or activated partial thromboplastin time \>1.5 times the upper limit of normal or fibrinogen less than 2 g/L
7. A requirement for therapeutic anticoagulant or antiplatelet drugs
8. Previously documented history of refractoriness to platelet transfusion secondary to HLA (Human Leukocyte Antigen) antibodies
9. Significant renal impairment (creatinine \>1.5 times the upper limit of normal)
10. Pregnant or breast-feeding
11. Unwilling or unable to provide informed consent
12. Participant has ever had a pulmonary embolism, deep vein thrombosis, cerebral thrombosis or has active angina
13. Participant has known history of subarachnoid hemorrhage
14. Participant has acquired disturbances to his/her colour vision
15. Participant has known sensitivity or allergy to Tranexamic Acid or any of its ingredients
16. The current use of oral contraceptive pill (Birth Control Pill), hormonal contraceptives or hormone replacement therapy .

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No